ASX-LISTED Medlab Clinical has received its license from the Victorian Government to sell or supply Schedule 8 or Schedule 9 Drugs in the form of cannabis and its derivatives, namely NanaBis (CBD:THC) and NanaBidial (CBD).
Because NanaBis is manufactured and distributed from Victoria, a licence was required to be provided from the State Government, but this licence also allowed Medlab to sell in other Australian states.
NanaBis is expected to be available in late Feb 2018 through the Special Access Scheme as announced last year (PD 24 Nov 17) and these licences are the next step in the commercialisation process of NanaBis, ceo Sean Hall said.
"Continued support from the medical community, the various states and Federal Government for cannabis-based medicine was pleasing," Hall said.
"We are seeking to make our medicines distinctive, giving medical practitioners, Government and industry stakeholders, such as the Australian Medical Association (AMA), confidence in prescribing our products.
"This Licence to Sell, combined with the recently renewed import licence (allowing for significant increases in the amounts of cannabis allowed to be imported [PD 27 Oct 17]) gives Medlab a significant advantage in being able to assist the medical community in treating advanced cancer pain."
MEANWHILE the Therapeutic Goods Administration has updated its Special Access Scheme forms to reflect changes to the Therapeutic Goods Regulations in relation to medicinal cannabis - tga.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 11 Jan 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 Jan 18
